A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) ...
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...
The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.
GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...
(HealthDay News) — The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist ...
These medications were sitagliptin, liraglutide, glimepiride, or insulin glargine U-100. Sitagliptin, liraglutide, and ...
Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...
Diabetes Care. 2015;38(6):1058-1066. The safety profile of liraglutide is under continuous surveillance through meticulous routine pharmacovigilance, with any cases of pancreatitis being analyzed ...
GLP-1 receptor agonists (GLP-1RAs), including liraglutide, semaglutide, and tirzepatide, were originally developed for managing type-2 diabetes. However, due to their success in helping with ...
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...
More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.